TRILUMINATE Pivotal Trial Results: Implications for the Heart Team

Published: 10 March 2023

  • Views:

    Views Icon 4666
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

In this short series of interviews, our faculty discuss the recent TRILUMINATE Pivotal Trial Results.

 

We hear from one of the lead PI’s on the trial, Dr Paul Sorajja (Abbott Northwestern Hospital, Minneapolis, US), as well as Cardiac Surgeon Dr Vinod Thourani (Piedmont Healthcare, Atlanta, US), Interventionalist Prof Ralph Stephan Von Bardeleben (Heart Valve Centre, Mainz, DE) and Heart Failure Specialist Dr Ulrich Jorde (Montefiore Medical Center, New York, US) to understand the implications from various members of the heart team.  
 
Recorded at ACC Congress 2023, New Orleans.

 

Want to learn more? 

 

Join this expert panel for a roundtable discussion entitled 'Tricuspid Regurgitation: How Will Valve Repair Change Our Practice?' taking place on 11 May 2023.

 

 

This programme is supported by an educational grant from Abbott.

Key Learning Objectives

  • Recall the key points of TRILUMINATE Pivotal, including trial design features and main outcomes
  • Summarise the potential impact of this trial for members of the heart team, including interventional cardiologists, surgeons and HF specialists
  • Outline how the outcomes achieved in this trial compare with surgical tricuspid repair
  • Identify patient groups most likely to benefit from transcatheter tricuspid valve repair

Target Audience

  • Cardiologists
  • Interventional Cardiologists
  • Surgeons
  • Heart Failure Specialists

More from this programme

Part 1

TRILUMINATE in a Nutshell: An Overview of Design & Results

Dr Sorajja provides a concise overview of the design and results of TRILUMINATE Pivotal and provides important context to the trial.

Part 2

Procedural Insights: What does TRILUMINATE Pivotal Mean to the Interventionalist?

Prof von Bardeleben discusses the procedural outcomes of the trial from the aspect of an interventionalist, and explains the likely impact on practice.

Part 3

A Surgical Comparison: How Can the Cardiac Surgeon Use This Data?

Dr Thourani explains how the results of TRILUMINATE Pivotal will impact patient selection and identifies the patient groups that would stand to achieve greater benefit from tricuspid valve repair over surgery.

Part 4

Perspective From a Heart Failure Specialist

Dr Jorde, a heart failure specialist, discusses the changes in KCCQ score achieved in TRILUMINATE Pivotal with tricuspid valve repair compared with medical therapy; he then posits how this changes the outlook for heart failure patients with severe, symptomatic tricuspid regurgitation at intermediate or greater surgical risk. 

Faculty Biographies

Paul Sorajja

Paul Sorajja

Director of the Center for Valve and Structural Heart Disease

Dr Paul Sorajja is an Interventional Cardiologist at the Minneapolis Heart Institute at Abbott Northwestern Hospital, where he is the Director of the Center for Valve and Structural Heart Disease.

Dr Sorajja's clinical practice specialises in interventional cardiology, with a focus on catheter-based therapy of valvular and structural heart disease. He was part of the team that performed the first transcatheter mitral valve replacement in the US for a patient with native mitral regurgitation in 2015, and has the highest worldwide experience with TMVR.

Dr Sorajja has published over 300 manuscripts and book chapters, with expertise in cardiac hemodynamics, clinical education, hypertrophic cardiomyopathy, and percutaneous therapy of structural heart disease. 

View full profile

Comments

You must be to comment. If you are not registered, you can register here.
adrian ionescu
11months
The finding that QOL was better in the intervention group is meaningless in the absence of a sham procedure in the medically-treated group. This is a negative trial, and the whole podcast a clumsy attempt at spinning the results.